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Abstract
Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical
management. The approach uses cytoreductive surgery which combines peritonectomy and
visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the
peritoneal cavity is flooded with chemotherapy solution in an attempt to eradicate residual disease.
In order to select patients for this approach the quantitative prognostic indicators for
carcinomatosis were reviewed, compared and contrasted. Prognostic indicators to be used to
select patients for this aggressive approach at the initiation of surgery and after completion of
cytoreduction were studied. Four quantitative assessments to be used at the time of abdominal
exploration were the Gilly staging, Japanese gastric cancer P score, peritoneal cancer index (PCI),
and the simplified peritoneal cancer index (SPCI). All have value with the PCI being the most
validated and most precise. Preoperative assessments include the tumor histopathology and the
prior surgical score. The completeness of cytoreduction score is an assessment of residual disease
after a maximal surgical effort. An opportunity for long-term survival following treatment for
carcinomatosis requires a complete cytoreduction in all reports for gastrointestinal cancer.
Quantitative prognostic indicators need to be knowledgeably employed when patients with
carcinomatosis are being treated. Improved patient selection with greater benefit and reduced
morbidity and mortality should result.
I. Introduction
Peritoneal carcinomatosis has always been regarded as a
terminal condition. It is present in 10 to 30% of patients
with gastrointestinal cancer at the time of their initial sur-
gery and is a frequent finding in patients who develop
recurrent cancer. Important natural history studies estab-
lish a 6-month median survival in this group of patients
[1-3]. Recent multicenter phase II and a single phase III
study evaluating the usefulness of cytoreductive surgery
and perioperative intraperitoneal chemotherapy are
promising [4,5]. Patient selection is of utmost importance
in optimizing the results of treatment and excluding
patients who will not benefit from a high morbidity and
potentially life threatening therapy.
Quantitative prognostic indicators are to serve as guide-
lines in the selection of treatments to maximize benefits
of therapy and to exclude patients who have little or no
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chance to improve. They are of greatest utility in high risk
and costly management protocols. Requirements of a use-
ful quantitative prognostic indicator include reproducibil-
ity, prediction of survivorship, and assessment of
morbidity and mortality. The goal is to establish manage-
ment protocols that standardize the decision making
process for multiple caregivers.
General surgery has used quantitative prognostic indica-
tors in the past with established benefit to patient care.
Examples of quantitative prognostic indicators currently
in use include Ranson's criteria, which estimates the risk
of life threatening complication or death in patients with
acute pancreatitis; and, the Child-Pugh score for liver cir-
rhosis, which evaluates the severity of liver disease corre-
lating grades with one- and two-year survival. Currently,
there are several clinical assessments at many different
institutions in use for the evaluation of carcinomatosis
(see Table 1). Our goal in this manuscript is to critically
discuss these quantitative prognostic indicators. Collabo-
rative studies between institutions would be greatly facili-
tated with standardized clinical tools for management of
carcinomatosis from gastrointestinal cancer.
II. Histopathology
In patients with carcinomatosis from gastrointestinal can-
cer, invasive implants are disseminated within the perito-
neal cavity. However, in two conditions the biological
aggressiveness of the disease will have a broad spectrum.
These two diseases are mucinous appendiceal malignan-
cies (oftentimes clinically designated pseudomyxoma
peritonei syndrome) and peritoneal mesothelioma. In
these diseases a non-invasive process may be widely dis-
seminated on the peritoneal surfaces. The biological
aggressiveness of the malignancy can be estimated by the
pathologist in a knowledgeable histologic review of mul-
tiple specimens. For pseudomyxoma peritonei syndrome,
the histologic classification described by Ronnett and col-
leagues has been most widely utilized [6].
Histopathologic examination categorizes the disease
process into disseminated peritoneal adenomucinosis
(DPAM), peritoneal mucinous carcinoma (PMCA) or a
hybrid type.
Disseminated Peritoneal Adenomucinosis
This is a minimally invasive disease, and therefore more
likely to be completely removed by cytoreduction using
peritonectomy. The histology of DPAM shows a bland
single layer of epithelium that surrounds lobules of
mucin. There are no signet rings and there is minimal aty-
pia. Invasion of the structures upon which tumor accumu-
lates does not occur. The primary site for DPAM is an
appendiceal adenoma which has minimally invaded the
wall of the appendix. Usually, the widespread intraperito-
neal dissemination of mucinous tumor is caused by a rup-
ture of the lumen of the appendix from pressure built up
by the malignant mucocele. Figure 1 shows the typical dis-
ruption of the wall of the appendix by tumor. Figure 2
presents the histologic character of DPAM.
Peritoneal Mucinous Adenocarcinoma
This is an invasive disease in which the mucinous cancer
cells show invasion into surrounding tissues. Sometimes,
the signet ring morphology or lymph node metastases are
present. The cancer cells will be found in multiple layers
surrounding the mucinous tumor globules. There is loss
Table 1: Quantitative prognostic indicators currently in use in 
patients with carcinomatosis.
Tumor histopathology
Intraoperative assessment of the extent of carcinomatosis at time of 
surgical exploration
• Gilly peritoneal carcinomatosis staging
• Carcinomatosis staging by the Japanese Research Society for Gastric 
Cancer
• Peritoneal Cancer Index (PCI)
• Dutch Simplified Peritoneal Carcinomatosis Index (SPCI)
CT PCI
Prior Surgical Score
Completeness of Cytoreduction Score
Right colon, terminal ileum and mucocele of the appendix Figure 1
Right colon, terminal ileum and mucocele of the appendix. 
This appendix is greatly dilated; the end has ruptured releas-
ing mucus and adenomatous epithelial cells into the free peri-
toneal cavity.International Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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of nuclear polarity and atypia is common. The quantity of
mucus may be variable from one patient to the other.
However, the PMCA histology may be associated with
very large amounts of mucoid ascites fluid. Therefore, it is
categorized as pseudomyxoma peritonei syndrome but
with an aggressive tumor histology. Figure 3 provides an
example of PMCA.
Hybrid Type Disease
In the hybrid type of mucinous carcinomatosis the field of
view for the pathologist shows 95% or more DPAM.
PMCA is present but in 5% or less of the total field of view
(figure 4). If there is more than 5% PMCA the histology is
no longer hybrid type but designated as PMCA.
Not surprisingly, the observation has been made by
numerous groups that the non-invasive mucinous tumors
(DPAM and hybrid type) are amenable to complete
cytoreduction. Therefore more definitive treatment and
improved survival using the combined approach is
expected with DPAM and hybrid type [7]. The histologic
and clinical differences between the different types of
mucinous appendiceal and other gastrointestinal muci-
nous tumors are shown in Table 2.
III. Intraperitoneal Assessment of the extent of 
Carcinomatosis
The quantitation of tumor found at the time of surgical
exploration of the abdomen has proven to be of value in
assessment of prognosis and treatment planning. Four dif-
ferent assessments have been published. They are listed in
Table 1.
Gilly Peritoneal Carcinomatosis Staging
The Gilly peritoneal carcinomatosis staging format was
first described in Lyon in 1994 [8]. This prognostic tool
takes into account the size of lesions found at operation
(table 3). Two advantages of this system are simplicity and
reproducibility. The utility of the Gilly staging device in
survivorship prediction has been demonstrated in the
multicentric prospective EVOCAPE study which gathered
data from 370 patients with peritoneal carcinomatosis
from non-gynecologic malignancies [2]. A significant dif-
ference was observed between stages 1 and 2 with a
median survival of 6 months and stages 3 and 4 whose
Histopathology of disseminated peritoneal adenomucinosis  (DPAM) Figure 2
Histopathology of disseminated peritoneal adenomucinosis 
(DPAM). (H+E × 200)
Histopathology of peritoneal mucinous adenomucinosis  (PMCA) Figure 3
Histopathology of peritoneal mucinous adenomucinosis 
(PMCA). (H+E × 700)
Histopathology of hybrid type mucinous appendiceal  malignancy Figure 4
Histopathology of hybrid type mucinous appendiceal malig-
nancy. (H+E × 100)International Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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median survival was 3 months. The Gilly carcinomatosis
staging has also been validated in patients having com-
bined treatment for carcinomatosis [9].
Although the Gilly system has been used for almost a dec-
ade with acceptable prognostic value, there are some crit-
icisms regarding this system. First, it should not be
designated a "staging system" because patients can only
be staged once in the course of their disease at the time of
diagnosis of the primary malignancy. Usually, a TNM
staging system is appropriate. The system might better be
called the Gilly prognostic index for carcinomatosis.
A second weakness of the Gilly prognostic index concerns
a failure to quantitate distribution of peritoneal surface
implants in the stage 3 and 4 categories. Carcinomatosis
confined to one portion of the abdomen may carry an
excellent prognosis even if the localized tumor implants
are of large size. If group III and group IV nodules by size
are diffuse throughout the whole abdomen, certainly a
much different prognosis would occur. A definitive
assessment of not only the size of the nodules but also the
distribution of carcinomatosis is necessary for the most
accurate assessment of prognosis.
The Japanese have proposed a quantitation of carcinoma-
tosis that is very simple, has been frequently applied, and
has been validated for gastric malignancy. For the original
staging a "P factor" is indicated for gastric cancer patients.
P-0 means that no carcinomatosis was seen by the surgeon
or could be established at the time of surgery. It would
currently include patients who are cytology positive for
gastric cancer cells. P-1 indicates implants immediately
adjacent to the stomach and above the transverse colon.
P-2 indicates scattered implants within the abdomen but
not of great number. P-3 indicates numerous implants
throughout the abdomen and pelvis.
Table 2: Histopathologic features of epithelial mucinous tumors of appendiceal, colonic, and small bowel origin are designated as 
disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA).
Features DPAM PMCA
Primary site Appendix Appendix, colon, small intestine
Primary diagnosis Mucinous adenoma usually in a mucocoele Mucinous adenocarcinoma
Surgical appearance Mucinous tumors and mucinous ascites with 
redistribution
Carcinomatosis with variable amounts of mucinous 
ascites, redistribution is prominent with large volume of 
ascites
Peritoneal tumor
• Cellularity Scant Moderate to abundant
• Morphology Abundant extracellular mucin containing simple to focally 
proliferative mucinous epithelium. There is a single layer 
of cells
Moderate to abundant extracellular mucin containing 
extensively proliferative mucinous epithelium or 
mucinous glands, clusters of cells, or individual cells 
consistent with carcinoma
• Cytologic atypia Minimal Moderate to marked
• Mitotic activity Rare Infrequent to frequent
Lymph node involvement Almost never Moderate
Liver metastases Almost never Very infrequent
Parenchymal organ invasion Rare (except ovary) Frequent
Hybrid type tumors show less than 5% of PMCA within DPAM. Mucinous carcinomas are divided into three grades by maintenance or loss of 
glandular architecture.
Table 3: Gilly peritoneal carcinomatosis staging.
Stage Peritoneal carcinomatosis description
Stage 0 No macroscopic disease
Stage 1 Malignant implants less than 5 mm in diameter Localized in one part of the abdomen
Stage 2 Diffuse to the whole abdomen
Stage 3 Malignant implants 5 mm to 2 cm
Stage 4 Large malignant nodules (more than 2 cm)International Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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This staging system can also be applied to patients who
have carcinomatosis with recurrent gastric cancer. A major
deficit of this staging system is its inability to accurately
locate the carcinomatosis. Also, it has no size assessment
of the cancerous implants. Although the P factor has been
of great value historically in the management of primary
gastric cancer as peritonectomy and intraperitoneal chem-
otherapy are used for treatment of carcinomatosis, a more
precise prognostic assessment is needed to manage gastric
cancer peritoneal seeding.
Peritoneal Cancer Index
The Peritoneal Cancer Index (PCI), like the other carcino-
matosis assessments, is determined at the time of surgical
exploration of the abdomen and pelvis. With invasive
cancer it serves as an estimate of probability of complete
Peritoneal cancer index (PCI) Figure 5
Peritoneal cancer index (PCI). Two transverse planes and two sagittal planes divide the abdomen into 9 regions. The upper 
transverse plane is located at the lowest aspect of the costal margin and the lower transverse plane is placed at the anterior 
superior iliac spine. The sagittal planes divide the abdomen into three equal sectors. The lines define the nine regions which are 
numbered in a clockwise direction with 0 at the umbilicus and 1 defining the space beneath the right hemidiaphragm. Regions 
9–12 divide the small bowel. Lesion size score is determined after complete lysis of all adhesions and the complete inspection 
of all parietal and visceral peritoneal surfaces. It refers to the greatest diameter of tumor implants that are distributed on the 
peritoneal surfaces. Primary tumors or localized recurrences at the primary site that can be removed definitively are excluded 
from the lesion size assessment. If there is confluence of disease matting abdominal or pelvic structures together, this is auto-
matically scored as L-3 even if it is a thin confluence of cancerous implants.International Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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cytoreduction and has been found to be an accurate
assessment of survival when cytoreductive surgery and
perioperative intraperitoneal chemotherapy are used as
treatment [10].
The PCI quantitatively combines the distribution of
tumor throughout 13 abdominopelvic regions with a
lesion size score. Two transverse and two sagittal planes
divide the abdomen into 9 regions. The upper transverse
plane is located at the lowest aspect of the costal margin,
and the lower transverse plane is placed at the anterior
superior iliac spine. The sagittal planes divide the
abdomen into three equal sectors. The lines define 9
regions, which are numbered in a clockwise direction with
0 at the umbilicus and 1 defining the space beneath the
right hemidiaphragm. Regions 9 through 12 divide the
small bowel into upper and lower jejunum and upper and
lower ileum (Figure 5). To make the PCI tool more quan-
titative and reproducible, each region is not only defined
by the surface landmarks as previously described, but can
also be defined by the anatomic structures found in each
region (Table 4).
The lesion size (LS) score is determined after complete
lysis of all adhesions and complete inspection of all
parietal and visceral peritonea surfaces within the abdom-
inopelvic regions. LS-0 indicates no implants seen. LS-1
indicates implants less than 0.25 cm. LS-2 indicates
implants between 0.25 and 2.5 cm. LS-3 indicates
implants greater than 2.5 cm. It refers to the greatest diam-
eter of tumor implants that are distributed on the perito-
neal surfaces. Primary tumors or localized recurrences at
the primary site that can be removed definitively are
excluded from the assessment. If there is a confluence of
disease matting abdominal or pelvic structures together,
this is automatically scored as LS-3 even if it is a thin layer
of cancerous implants.
The lesion sizes are then summated for all abdominopel-
vic regions. The extent of the disease within all regions of
the abdomen and pelvis is indicated by a numerical score
from 0 to 39.
In 1995, Sugarbaker and Jablonski published that the PCI
was a meaningful assessment for colon cancer but not for
mucinous appendiceal tumors [11]. Elias et al., found sur-
vival to be more favorable in those patients with
carcinomatosis from colon cancer with a PCI score of less
than 16 [12]. In a larger number of patients Sugarbaker
and Chang established survivorship using the PCI [13].
Five-year survival was 50% in colon cancer patients with
carcinomatosis with a PCI less than 10, 20% for 11–20
and 0% in those with a PCI score greater than 20 (Figure
6). Tentes and colleagues validated the PCI for ovarian
cancer [14]. The PCI is not only useful as a prognostic
indicator but also as a guide for sequential determinations
of volume of carcinomatosis over time estimating the like-
lihood of a complete cytoreduction at re-operative surgery
[15].
This quantitative prognostic indicator for colon carcino-
matosis established that for patients scoring greater than
20, palliation is the goal of treatment. Currently, a PCI of
greater than 20 is regarded as a relative contraindication to
an elective intervention for carcinomatosis from colon
cancer. It is associated with a low median survival, approx-
imately the same as median survival without surgical
intervention. In patients who have a PCI greater than 20,
palliative surgery is indicated in order to alleviate symp-
toms or to prevent symptoms that may occur in the near
future. In an asymptomatic patient with colon
Table 4: Anatomic structures involved in the 13 abdominopelvic regions of the peritoneal cancer index (PCI).
Regions Anatomic structures
0 Central Midline abdominal incision – entire greater omentum – transverse colon
1 Right upper Superior surface of the right lobe of the liver – undersurface of the right hemidiaphragm – right retro hepatic space
2 Epigastrium Epigastric fat pad – left lobe of the liver – lesser omentum – falciform ligament
3 Left upper Undersurface of the left hemidiaphragm – spleen – tail of pancreas – anterior and posterior surfaces of the stomach
4 Left flank Descending colon – left abdominal gutter
5 Left lower Pelvic sidewall lateral to the sigmoid colon – sigmoid colon
6 Pelvis Female internal genitalia with ovaries, tubes and uterus – bladder, Douglas pouch – rectosigmoid colon
7 Right lower Right pelvic sidewall – cecum – appendix
8 Right flank Right abdominal gutter – ascending colon
9 Upper jejunum
10 Lower jejunum
11 Upper ileum
12 Lower ileumInternational Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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carcinomatosis cytoreductive surgery with intraperitoneal
chemotherapy with cure as a goal of treatment is probably
not indicated.
An exception to the utility of the PCI is found in treating
patients with pseudomyxoma peritonei and minimally
aggressive mesothelioma. Because the disease is non-inva-
sive, a PCI of 39 can be converted to 0 by cytoreductive
surgery. There is a low probability of recurrence after com-
plete cytoreduction with perioperative intraperitoneal
chemotherapy and therefore the PCI has no prognostic
implication [7].
Another caveat that must be observed when using the PCI
occurs in cases in which a low PCI score is recorded in the
presence of invasive cancer at a crucial anatomic site. For
example, at exploration one may find invasive tumor in
and around the common bile duct with little disease else-
where. Even thought the PCI is low, a complete
cytoreduction may not be possible. In these cases, invasive
cancer at a crucial anatomic site places the patient into the
same category as would systemic metastasis in the lungs or
bone. Only palliative surgery is indicated if residual dis-
ease post-cytoreduction will be present.
Simplified Peritoneal Cancer Index
The Simplified Peritoneal Cancer Index (SPCI) was estab-
lished at the Netherlands Cancer Institute and has been
used for colorectal and appendieal cancer staging (Table
5). This tool has prognostic implication for survival fol-
lowing cytoreductive surgery and hyperthermic intraperi-
toneal chemotherapy [16].
Verwaal and colleagues have provided important infor-
mation regarding the relationship of the Simplified
Peritoneal Cancer Index and the incidence of complica-
tions in patients who receive combined treatment [17]. In
their review of the toxicity of combined treatment,
complications increased when the cancer index recorded
involvement of more than five regions (p = 0.044). Also,
if the patient had recurrent colon cancer (as opposed to
carcinomatosis with primary cancer) or if there was an
incomplete cytoreduction, the incidence of complications
was significantly higher. Verwaal et al., established that
the peritoneal cancer index quantitated not only the sur-
vival outcome of these patients but also the expected mor-
bidity and mortality of the combined treatment [16].
There are marked similarities between the SPCI and the
PCI. Both the anatomic distribution of the tumor masses
and the size of the tumor masses within each abdominal
region are indicated. In the PCI, there are 13 anatomic
sites designated by a diagram; in the Dutch SPCI, there are
7 anatomic regions designated by anatomic site. In both
systems the volume of tumor in each region is to be scored
quantitatively. Some shortcomings of the SPCI could be
formulated. First, the epigastric region, very important in
determining the completeness of cytoreduction in some
diseases is not designated separately. Disease above the
stomach in the lesser omental region may cause the
cytoreduction to be incomplete [15].
A second major criticism of the Dutch SPCI concerns their
misuse of their own tool. In their recent publications they
perform a survival analysis by SPCI and a toxicity
assessment by the SPCI. However, only the involvement
of regions 0–7 was indicated. No tumor size in the regions
was indicated [16,17].
Peritoneal carcinomatosis from colon malignancy survival by  peritoneal cancer index Figure 6
Peritoneal carcinomatosis from colon malignancy survival by 
peritoneal cancer index. (Modified from Reference 13)
Table 5: Simplified Peritoneal Cancer Index
◆  Tumor is recorded as:
indent="1" • Large (> 5 cm)
indent="1" • Moderate (1–5 cm)
indent="1" • Small (< 1 cm)
indent="1" • None
◆  Seven abdominal regions:
indent="1" • I: pelvis
indent="1" • II: right lower abdomen
indent="1" • III: greater omentum, transverse colon and spleen
indent="1" • IV: right subdiaphragmatic area
indent="1" • V: left subdiaphragmatic area
indent="1" • VI: subhepatic and lesser omental area
indent="1" • VII: small bowel and small bowel mesenteryInternational Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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Prior Surgical Score
An accepted fact regarding cancer treatment is that the
optimal treatment with the highest cure rate, the greatest
preservation of function, and the lowest morbidity and
mortality is the initial treatment. In the management of
carcinomatosis the extent of prior resection before defini-
tive cytoreduction with intraperitoneal chemotherapy has
a negative impact on the survival. This occurs because of
the cancer cell entrapment phenomenon. Surgery opens
tissue planes whose raw surface is a favored site for cancer
cell adherence, vascularization and progression. In the use
of combined treatment for carcinomatosis, the non-trau-
matized peritoneal surface is the body's first line of
defense against carcinomatosis. Cancer progression deep
to peritoneal surfaces, especially disease imbedded in scar,
is difficult or impossible to remove by peritonectomy or
to eradicate by intraperitoneal chemotherapy.
The prior surgical score (PSS) quantitates the extent of sur-
gery prior to definitive combined treatment. It shows that
the greater the surgery the poorer the results of
carcinomatosis treatment. The assessment uses a diagram
similar to that for PCI but excludes abdominopelvic
regions 9–12. For a PSS of 0 no prior surgery or only a
biopsy was performed; PSS of 1 indicates one region with
prior surgery; PSS-2 indicates 2 to 5 regions previously dis-
sected; PSS-3 indicates more than 5 regions previously
dissected. This is equivalent to a prior attempt at complete
cytoreduction but in the absence of perioperative intra-
peritoneal chemotherapy. In appendiceal cancer patients
with a prior surgical score of 0–2, the survival using com-
bined treatment was 70% at 5 years; with a prior surgical
score of 3, the 5-year survival was 51% (p = 0.001) [18].
Completeness of Cytoreduction Score
The Completeness of Cytoreduction Score functions as a
major prognostic indicator for the survival in peritoneal
mesothelima, colon cancer with carcinomatosis, gastric
cancer with carcinomatosis and sarcomatosis [7]. It is to
be assessed after cytoreductive surgery is completed. Com-
plete cytoreduction (CC-0 or CC-1) or incomplete (CC-2
or CC-3) are determined. A CC-0 is apparent when there
is no peritoneal seeding visualized within the operative
field. CC-1 indicates nodules persisting after cytoreduc-
tion less than 2.5 cm. CC-2 has nodules between 2.5 and
5 cm, whereas a CC-3 indicates nodules greater than 5 cm
or a confluence of unresectable tumor nodule at any site
within the abdomen or pelvis. The CC-1 tumor nodule
size is thought to be penetrable by intracavitary chemo-
therapy and is, therefore, designated as complete
cytoreduction if perioperative intraperitoneal chemother-
apy is used.
Sugarbaker and colleagues found that prognosis can be
estimated by completeness of cytoreduction. For colon
cancer as shown in Figure 7, there is a 40% chance of sur-
vival at 5 years in those who undergo complete cytoreduc-
tion versus 0% survival in the incomplete category [7,13].
Numerous other groups have confirmed the complete
cytoreduction as a requirement for survival after treatment
of carcinomatosis from appendiceal, colorectal and gastric
cancer [4,9,11,12,16-19].
Although no formal statement in the literature is availa-
ble, it is thought that the definition of complete vs.
incomplete cytoreduction varies with the histologic type
of the malignancy. For example, mucinous tumors by dif-
fusion are well penetrated with intraperitoneal
chemotherapy solutions. With minimally invasive muci-
nous tumors such as pseudomyxoma peritonei, complete
cytoreduction may occur in the combined treatment plan
with tumor nodules up to a full centimeter in size. In con-
trast, hard fibrotic non-mucinous colon cancer is poorly
penetrated by chemotherapy solution. Only cytoreduc-
tion down to no visible evidence of disease would be
expected to result in long-term survival with a sclerotic
malignant process. Also, some cancers may be remarkably
more responsive to chemotherapy than others. This is
likely the case with a majority of ovarian cancers. Their
complete response to systemic chemotherapy is also fre-
quently seen with intraperitoneal chemotherapy solu-
tions or a bidirectional (intraperitoneal combined with
intravenous chemotherapy) approach. In both these situ-
ations the definition of a complete cytoreduction scored
Peritoneal carcinomatosis from colon malignancy survival by  cytoreduction Figure 7
Peritoneal carcinomatosis from colon malignancy survival by 
cytoreduction. (Modified from Reference 13)International Seminars in Surgical Oncology 2005, 2:3 http://www.issoonline.com/content/2/1/3
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by a CC-1 designation would vary with the clinical
situation.
Computerized Tomographic PCI
The preoperative CT is an excellent tool in locating and
quantifying mucinous adenocarcinoma within the perito-
neal cavity [20]. Unfortunately, with intestinal histologic
type of colon cancer the accuracy of the CT is considerably
reduced [21]. However, for mucinous carcinomatosis CT
scanning is an accurate prognostic indicator of the
possibility of resectability. It may show segmental
obstruction of the small bowel or tumor nodules greater
than 5 cm on small bowel. Patients who have both of
these findings have a likelihood of less than 5% of com-
plete cytoreduction. Obstructed segments of bowel signal
an invasive character of malignancy on small bowl sur-
faces that would be unlikely to be completely cytore-
duced. Large tumor nodules on small bowel or its
mesentery are unlikely to be adequately cytoreduced with-
out visceral resection.
There are some special demands on CT scanning if the
radiologic examination is to be optimized. Bowel loops
cut in cross section are often indistinguishable from
cancer nodules. Only if maximal oral contrast using a bar-
ium sulfate compound is utilized to prepare the patient
for this examination can the greatest accuracy and the
greatest prognostic implications of the examination be
realized.
Another technical requirement is the imaging of solid
tumor layered out on the peritoneal surfaces. Unless there
is maximal intravenous contrast with a 60 to 120 second
delay after contrast infusion will the confluence of malig-
nancy as a thin layer on the peritoneum be imaged. In
some patients, the solid tumor, or semisolid tumor may
be distributed to appear as ascites on abdominal and pel-
vic CT. Much to the surgeon's dismay, upon opening the
abdomen, a solid tumor mass filling the abdomen and
pelvis and causing adherence of small bowel and small
bowel mesentery will be revealed. In this situation, not
even palliative surgery can be safely performed. In
patients who clinically have a firm abdomen and in
whom the surgeon suspects large volume of solid tumor,
an ultrasound examination may be required in order to
confirm an ascitic versus a solid component of the
abdominal and pelvic malignancy. If ultrasound shows
that there is only minimal or no ascites and that the large
volume of tumor is solid or semisolid, surgical interven-
tions are not beneficial. It is better to determine the nature
of the carcinomatosis radiologically than at the time of a
major surgical exploration.
Conclusion
Quantitative prognostic indicators are of value in manage-
ment of peritoneal surface malignancy from gastrointesti-
nal cancer. Preoperative CT PCI, intraoperative PCI and
postresection CC score have all been reported valuable. As
one knowledgeable applies these tests, proper selection of
patients for combined treatment may increase benefit and
decrease morbidity and mortality.
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